Super Bowl, Novartis and breast cancer
Novartis' first Super Bowl ad aims to 'create a movement' with breast cancer awareness blitz
To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s biggest stages. | To direct more attention toward the importance of regular breast cancer screenings,
Novartis taps Hailee Steinfeld, Wanda Sykes for breast cancer Super Bowl ad
In addition to the partnership with Steinfeld and Sykes, Novartis is collaborating on awareness efforts and advocacy events with organizations like the Susan G. Komen, Living Beyond Breast Cancer, TOUCH (The Black Breast Cancer Alliance) and Breastcancer.org.
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from ...
Novartis (NYSE:NVS) and MSN Pharmaceuticals have reached agreement in a Delaware federal court to dismiss patent litigation ...
AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.
SALES FORECAST: Novartis's sales are forecast at $12.78 billion, according to analysts' estimates compiled by Visible Alpha. This compares with $11.42 billion the year before. Shares rose 5.1% over ...
ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...
Novartis Pharmaceuticals Corporation v. Torrent Pharma Inc., No. 23-2218 (Fed. Cir. 2025) — On January 10, 2025, the Federal Circuit reversed ...
In Novartis Pharms. Corp. v. Torrent Pharma Inc., the U. S. Court of Appeals for the Federal Circuit shut down efforts to market a generic version of the heart disease drug ENTRESTO which is sold ...
Mumbai: In a fresh challenge to Novartis' blockbuster heart failure drug Entresto, Indian generics maker Lupin has received ...
Novartis AG (NYSE:NVS), a global healthcare company valued at over $206 billion, has undergone significant transformation in recent years, focusing its efforts on becoming a pure-play pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback